董事介绍
注:董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Luke Faulstick | 男 | Director | 53 | 24.53万美元 | 未持股 | 2017-04-28 |
| Lilly Marks | 女 | Director | 69 | 23.53万美元 | 未持股 | 2017-04-28 |
| Michael E. Paolucci | 男 | Director | 57 | 55.29万美元 | 未持股 | 2017-04-28 |
| Maria Sainz | 女 | Director | 51 | 24.53万美元 | 未持股 | 2017-04-28 |
| Bradley R. Mason | 男 | President and Chief Executive Officer and Director | 63 | 483.38万美元 | 未持股 | 2017-04-28 |
| Guy J. Jordan | 男 | Director | 68 | 24.53万美元 | 未持股 | 2017-04-28 |
| Maria Sainz | 女 | Director | 51 | 未披露 | 未持股 | 2017-04-28 |
| Alexis V. Lukianov | 男 | Director | 61 | 32.95万美元 | 未持股 | 2017-04-28 |
| Maria Sainz | 女 | Director | 51 | 未披露 | 未持股 | 2017-04-28 |
| James F. Hinrichs | 男 | Director | 49 | 25.03万美元 | 未持股 | 2017-04-28 |
| Anthony F. Martin | 男 | Director | 62 | 23.53万美元 | 未持股 | 2017-04-28 |
| Ronald Matricaria | 男 | Chairman | 74 | 46.96万美元 | 未持股 | 2017-04-28 |
高管介绍
注:高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Doug Rice | 男 | Chief Financial Officer | 51 | 131.92万美元 | 未持股 | 2017-04-28 |
| Bradley R. Mason | 男 | President and Chief Executive Officer and Director | 63 | 483.38万美元 | 未持股 | 2017-04-28 |
董事简历
中英对照 |  中文 |  英文- Luke Faulstick
-
Luke Faulstick,他于2014年9月加入董事会。他拥有25年以上的生产主管任职经验。他是公认的精益生产和工作文化专家他是Power Partners Inc.的联席所有者、总裁和首席执行官,以及DJO Global的前任执行副总裁兼首席运营官。他此前曾担任高级运营管理职务,任职于Tyco Healthcare、Graphic Controls、Mitsubishi Consumer Electronics、Eastman Kodak。在他的领导下,DJO Global的运营团队和制造厂赢得了众多奖项,包括the Shingo Prize for Operational Excellence、Industry Week’s Best Plants、 the Association of Manufacturing Excellence Operational Excellence Award。他获得Michigan State University的工程科学学士学位,以及Rochester Institute of Technology的工程硕士学位。他此前曾任职于Alphatec Spine and Microdental的董事会,以及the Association of Manufacturing Excellence的董事会主席。他目前是the Rady Children’s Hospital Foundation的监事会成员,以及the UCLA Anderson School of Business的董事会成员。
Luke Faulstick joined the Board in September 2014. He has over 25 years of experience as a manufacturing executive and is a recognized expert on Lean Manufacturing and work culture. Mr. Faulstick is co-owner, President and Chief Executive Officer of Power Partners Inc. and formerly the Executive Vice President and Chief Operating Officer of DJO Global. He previously held senior operating management roles at Tyco Healthcare, Graphic Controls, Mitsubishi Consumer Electronics and Eastman Kodak. Under his leadership, DJO Global’s operations teams and manufacturing plants won numerous awards including the Shingo Prize for Operational Excellence, Industry Week’s Best Plants, and the Association of Manufacturing Excellence Operational Excellence Award. Mr. Faulstick received a Bachelor of Science Degree in Engineering from Michigan State University and a Master of Science Degree in Engineering from Rochester Institute of Technology. He previously served on the boards of Alphatec Spine and Microdental, as well as Chairman of the Board of the Association of Manufacturing Excellence. Currently he is a member of the Rady Children’s Hospital Foundation Board of Trustees and a Certified Board of Director through the UCLA Anderson School of Business. - Luke Faulstick,他于2014年9月加入董事会。他拥有25年以上的生产主管任职经验。他是公认的精益生产和工作文化专家他是Power Partners Inc.的联席所有者、总裁和首席执行官,以及DJO Global的前任执行副总裁兼首席运营官。他此前曾担任高级运营管理职务,任职于Tyco Healthcare、Graphic Controls、Mitsubishi Consumer Electronics、Eastman Kodak。在他的领导下,DJO Global的运营团队和制造厂赢得了众多奖项,包括the Shingo Prize for Operational Excellence、Industry Week’s Best Plants、 the Association of Manufacturing Excellence Operational Excellence Award。他获得Michigan State University的工程科学学士学位,以及Rochester Institute of Technology的工程硕士学位。他此前曾任职于Alphatec Spine and Microdental的董事会,以及the Association of Manufacturing Excellence的董事会主席。他目前是the Rady Children’s Hospital Foundation的监事会成员,以及the UCLA Anderson School of Business的董事会成员。
- Luke Faulstick joined the Board in September 2014. He has over 25 years of experience as a manufacturing executive and is a recognized expert on Lean Manufacturing and work culture. Mr. Faulstick is co-owner, President and Chief Executive Officer of Power Partners Inc. and formerly the Executive Vice President and Chief Operating Officer of DJO Global. He previously held senior operating management roles at Tyco Healthcare, Graphic Controls, Mitsubishi Consumer Electronics and Eastman Kodak. Under his leadership, DJO Global’s operations teams and manufacturing plants won numerous awards including the Shingo Prize for Operational Excellence, Industry Week’s Best Plants, and the Association of Manufacturing Excellence Operational Excellence Award. Mr. Faulstick received a Bachelor of Science Degree in Engineering from Michigan State University and a Master of Science Degree in Engineering from Rochester Institute of Technology. He previously served on the boards of Alphatec Spine and Microdental, as well as Chairman of the Board of the Association of Manufacturing Excellence. Currently he is a member of the Rady Children’s Hospital Foundation Board of Trustees and a Certified Board of Director through the UCLA Anderson School of Business.
- Lilly Marks
-
Lilly Marks,她于2015年6月被任命到我们的董事会。她目前担任the University of Colorado的健康事务副总裁,也曾领导安舒茨医学科罗拉多大学校园(the University of Colorado Anschutz Medical Campus)。她是the University of Colorado Health System、Children’s Hospital Colorado、 Federal Reserve Bank of Kansas City、the Advisory Board for Clinical Research of the National Institutes of Health、the Fitzsimons Redevelopment Authority、the Association of Academic Health Centers AAHC、the Global Down Syndrome Foundation 、the Rose Community Foundation的现任董事会成员。此外,她是the Association of American Medical Colleges (AAMC) Advisory Panel on Research的成员,以及the University of Colorado Foundation的受托人。她毕业于the University of Colorado。
Lilly Marks was appointed to the Board in June 2015. She currently serves as the Vice President for Health Affairs for the University of Colorado and has led the University of Colorado Anschutz Medical Campus. Ms. Marks is also currently a member of the Board of Directors of the University of Colorado Health System, Children's Hospital Colorado, Federal Reserve Bank of Kansas City, the Advisory Board for Clinical Research of the National Institutes of Health, the Fitzsimons Redevelopment Authority, the Association of Academic Health Centers AAHC, the Global Down Syndrome Foundation and the Rose Community Foundation. Additionally, she is a member of the Association of American Medical Colleges (AAMC) Advisory Panel on Research and is a trustee of the University of Colorado Foundation. Ms. Marks is a graduate of the University of Colorado. - Lilly Marks,她于2015年6月被任命到我们的董事会。她目前担任the University of Colorado的健康事务副总裁,也曾领导安舒茨医学科罗拉多大学校园(the University of Colorado Anschutz Medical Campus)。她是the University of Colorado Health System、Children’s Hospital Colorado、 Federal Reserve Bank of Kansas City、the Advisory Board for Clinical Research of the National Institutes of Health、the Fitzsimons Redevelopment Authority、the Association of Academic Health Centers AAHC、the Global Down Syndrome Foundation 、the Rose Community Foundation的现任董事会成员。此外,她是the Association of American Medical Colleges (AAMC) Advisory Panel on Research的成员,以及the University of Colorado Foundation的受托人。她毕业于the University of Colorado。
- Lilly Marks was appointed to the Board in June 2015. She currently serves as the Vice President for Health Affairs for the University of Colorado and has led the University of Colorado Anschutz Medical Campus. Ms. Marks is also currently a member of the Board of Directors of the University of Colorado Health System, Children's Hospital Colorado, Federal Reserve Bank of Kansas City, the Advisory Board for Clinical Research of the National Institutes of Health, the Fitzsimons Redevelopment Authority, the Association of Academic Health Centers AAHC, the Global Down Syndrome Foundation and the Rose Community Foundation. Additionally, she is a member of the Association of American Medical Colleges (AAMC) Advisory Panel on Research and is a trustee of the University of Colorado Foundation. Ms. Marks is a graduate of the University of Colorado.
- Michael E. Paolucci
-
Michael E. Paolucci ,2016年3月被提名进入董事会和赔偿委员会。一位经验丰富的人力资源主管,Paolucci先生拥有超过20年的直接与董事会和提高组织能力和人力资源计划的执行者,使企业绩效的持续改进的全球工作经验。他目前在晚期肿瘤和癌症研究的前沿生物制药公司Halozyme Therapeutics Inc.中担任联盟和人力资本主管,他负责管理公司联盟和大型制药合作伙伴和人力资源策略、程序和政策关系。在Halozyme之前,Paolucci 先生担任CareFusion执行副总裁和首席人力资源官。他也曾在NuVasive担任人力资源执行副总裁,并在Life Technologies待了5年。他也曾在Hewlett Packard服务部门担任人力资源主管,并在被Hewlett Packard收购的EDS担任多个领导职位。在HP/EDS之前,他在是人力资源咨询公司Towers Perrin中担任合伙人。Paolucci先生毕业于Ohio State University。
Michael E. Paolucci was named to the Board of Directors and appointed to the Compensation Committee in March 2016. A seasoned Human Resource HR executive, Mr. Paolucci has more than 20 years of global experience working directly with Boards of Directors and C-level executives to improve organizational capabilities and HR programs that result in sustained improvements in business performance. He currently serves as Vice President and Chief Human Resources Officer for Halozyme Therapeutics Inc., a late stage oncology and biopharmaceutical company on the forefront of cancer research where he is responsible for its human resource strategies, programs, and policies. Prior to Halozyme, Mr. Paolucci served as Executive Vice President and Chief Human Resource Officer for CareFusion. He also served as Executive Vice President of Human Resources at NuVasive, and spent five years at Life Technologies. He was head of Human Resources for the services division of Hewlett Packard and served in several leadership roles with EDS, which was acquired by Hewlett Packard. Prior to HP/EDS, he was a partner with the HR consulting firm Towers Perrin. Mr. Paolucci is a graduate of Ohio State University. - Michael E. Paolucci ,2016年3月被提名进入董事会和赔偿委员会。一位经验丰富的人力资源主管,Paolucci先生拥有超过20年的直接与董事会和提高组织能力和人力资源计划的执行者,使企业绩效的持续改进的全球工作经验。他目前在晚期肿瘤和癌症研究的前沿生物制药公司Halozyme Therapeutics Inc.中担任联盟和人力资本主管,他负责管理公司联盟和大型制药合作伙伴和人力资源策略、程序和政策关系。在Halozyme之前,Paolucci 先生担任CareFusion执行副总裁和首席人力资源官。他也曾在NuVasive担任人力资源执行副总裁,并在Life Technologies待了5年。他也曾在Hewlett Packard服务部门担任人力资源主管,并在被Hewlett Packard收购的EDS担任多个领导职位。在HP/EDS之前,他在是人力资源咨询公司Towers Perrin中担任合伙人。Paolucci先生毕业于Ohio State University。
- Michael E. Paolucci was named to the Board of Directors and appointed to the Compensation Committee in March 2016. A seasoned Human Resource HR executive, Mr. Paolucci has more than 20 years of global experience working directly with Boards of Directors and C-level executives to improve organizational capabilities and HR programs that result in sustained improvements in business performance. He currently serves as Vice President and Chief Human Resources Officer for Halozyme Therapeutics Inc., a late stage oncology and biopharmaceutical company on the forefront of cancer research where he is responsible for its human resource strategies, programs, and policies. Prior to Halozyme, Mr. Paolucci served as Executive Vice President and Chief Human Resource Officer for CareFusion. He also served as Executive Vice President of Human Resources at NuVasive, and spent five years at Life Technologies. He was head of Human Resources for the services division of Hewlett Packard and served in several leadership roles with EDS, which was acquired by Hewlett Packard. Prior to HP/EDS, he was a partner with the HR consulting firm Towers Perrin. Mr. Paolucci is a graduate of Ohio State University.
- Maria Sainz
-
Maria Sainz,Sainz女士自2018年4月起担任公司董事。Sainz女士于2012年5月至2017年7月担任Cardiokinetix Inc.(一家开发经导管植入物的私人公司)的总裁,首席执行官兼董事。Sainz女士于2011年10月至2012年5月被史赛克公司收购,担任神经血管医疗技术公司Concentric Medical,Inc.的总裁兼首席执行官。Sainz女士曾担任Guidant Corporation/Boston Scientific心脏外科部门的总裁,在担任该职位之前,曾担任多个职责递增的销售与市场营销管理职位。Sainz女士目前在Orthofix International NV,Halyard Health,Inc.和MRI Interventions的董事会任职。Sainz女士拥有西班牙马德里the University Complutense的语言硕士学位和美国国际管理研究生院的国际管理硕士学位。
Maria Sainz, Ms. Sainz has served as a director of the Company since April 2018. Ms. Sainz served as the President, Chief Executive Officer, and Director of CardioKinetix Inc., a private company that developed transcatheter implants from May 2012 to July 2017. Ms. Sainz was the President and Chief Executive Officer of Concentric Medical, Inc., a neurovascular medical technology company, through its acquisition by Stryker Corporation in October 2011 until May 2012. Ms. Sainz served as the President of the Cardiac Surgery division of Guidant Corporation/Boston Scientific and prior to that position in several sales and marketing management positions of increasing responsibility. Ms. Sainz currently serves on the board of directors of Orthofix International NV, Halyard Health, Inc. and MRI Interventions. Ms. Sainz holds a M.A. in Languages from the University Complutense in Madrid, Spain and a Master's Degree in International Management from the American Graduate School of International Management. - Maria Sainz,Sainz女士自2018年4月起担任公司董事。Sainz女士于2012年5月至2017年7月担任Cardiokinetix Inc.(一家开发经导管植入物的私人公司)的总裁,首席执行官兼董事。Sainz女士于2011年10月至2012年5月被史赛克公司收购,担任神经血管医疗技术公司Concentric Medical,Inc.的总裁兼首席执行官。Sainz女士曾担任Guidant Corporation/Boston Scientific心脏外科部门的总裁,在担任该职位之前,曾担任多个职责递增的销售与市场营销管理职位。Sainz女士目前在Orthofix International NV,Halyard Health,Inc.和MRI Interventions的董事会任职。Sainz女士拥有西班牙马德里the University Complutense的语言硕士学位和美国国际管理研究生院的国际管理硕士学位。
- Maria Sainz, Ms. Sainz has served as a director of the Company since April 2018. Ms. Sainz served as the President, Chief Executive Officer, and Director of CardioKinetix Inc., a private company that developed transcatheter implants from May 2012 to July 2017. Ms. Sainz was the President and Chief Executive Officer of Concentric Medical, Inc., a neurovascular medical technology company, through its acquisition by Stryker Corporation in October 2011 until May 2012. Ms. Sainz served as the President of the Cardiac Surgery division of Guidant Corporation/Boston Scientific and prior to that position in several sales and marketing management positions of increasing responsibility. Ms. Sainz currently serves on the board of directors of Orthofix International NV, Halyard Health, Inc. and MRI Interventions. Ms. Sainz holds a M.A. in Languages from the University Complutense in Madrid, Spain and a Master's Degree in International Management from the American Graduate School of International Management.
- Bradley R. Mason
-
Bradley R. Mason。去年年度股东大会开始,Mason先生担任董事。Mason先生在2013年3月重新加入Orthofix作为我们的总裁兼首席执行官,在此前,2008年6月到2009年10月担任北美州集团总裁,2009年11月到2010年10月担任战略顾问。被任命为北美州集团总裁之前,自2003年12月公司收购Breg Orthofix Inc.他担任公司的副总裁。在Orthofix收购之前,Mason先生担任 Breg的总裁和主席,他与其他五个股东成立于1989年的一家公司。Mason先生在医疗器械行业有超过25年的经验,其中一些在dj Orthopedics共同渡过,在那他是创始人兼执行副总裁。自2010年从Orthofix退休,他曾担任各种兼职咨询及顾问角色,包括2012年10月以来担任Orthofix顾问(咨询关系已经于2013年3月13日终)。Mason先生在骨科产品有了38个颁发专利。他最优异成绩毕业于MiraCosta College,获得文科副学士学位和理科副学士学位。
Bradley R. Mason has served as a director since the 2013 Annual General Meeting. Mr. Mason rejoined Orthofix in March 2013 as our President and Chief Executive Officer after previously serving as Group President, North America from June 2008 through October 2009 and as a Strategic Advisor from November 2009 through October 2010. Prior to being appointed as Group President, North America, he had served as a Vice President of the Company since December 2003 when the Company acquired Breg, Inc. Prior to its acquisition by Orthofix, Mr. Mason had served as President and Chairman of Breg, a company he principally founded in 1989 with five other shareholders. Mr. Mason has over 30 years of experience in the medical device industry, some of which were spent with dj Orthopedics formally DonJoy where he became an owner and executive in its early development stage and held the position of Executive Vice President. Since his retirement from Orthofix in 2010 he has served in a variety of part-time consulting and advisory roles, including as a consultant to Orthofix since October 2012 (which consulting relationship has been terminated as of March 13 2013). Mr. Mason is the named inventor on 38 issued patents in the orthopedic product arena. He graduated Summa Cum Laude with an Associate of Arts and Associate of Science degree from MiraCosta College. - Bradley R. Mason。去年年度股东大会开始,Mason先生担任董事。Mason先生在2013年3月重新加入Orthofix作为我们的总裁兼首席执行官,在此前,2008年6月到2009年10月担任北美州集团总裁,2009年11月到2010年10月担任战略顾问。被任命为北美州集团总裁之前,自2003年12月公司收购Breg Orthofix Inc.他担任公司的副总裁。在Orthofix收购之前,Mason先生担任 Breg的总裁和主席,他与其他五个股东成立于1989年的一家公司。Mason先生在医疗器械行业有超过25年的经验,其中一些在dj Orthopedics共同渡过,在那他是创始人兼执行副总裁。自2010年从Orthofix退休,他曾担任各种兼职咨询及顾问角色,包括2012年10月以来担任Orthofix顾问(咨询关系已经于2013年3月13日终)。Mason先生在骨科产品有了38个颁发专利。他最优异成绩毕业于MiraCosta College,获得文科副学士学位和理科副学士学位。
- Bradley R. Mason has served as a director since the 2013 Annual General Meeting. Mr. Mason rejoined Orthofix in March 2013 as our President and Chief Executive Officer after previously serving as Group President, North America from June 2008 through October 2009 and as a Strategic Advisor from November 2009 through October 2010. Prior to being appointed as Group President, North America, he had served as a Vice President of the Company since December 2003 when the Company acquired Breg, Inc. Prior to its acquisition by Orthofix, Mr. Mason had served as President and Chairman of Breg, a company he principally founded in 1989 with five other shareholders. Mr. Mason has over 30 years of experience in the medical device industry, some of which were spent with dj Orthopedics formally DonJoy where he became an owner and executive in its early development stage and held the position of Executive Vice President. Since his retirement from Orthofix in 2010 he has served in a variety of part-time consulting and advisory roles, including as a consultant to Orthofix since October 2012 (which consulting relationship has been terminated as of March 13 2013). Mr. Mason is the named inventor on 38 issued patents in the orthopedic product arena. He graduated Summa Cum Laude with an Associate of Arts and Associate of Science degree from MiraCosta College.
- Guy J. Jordan
-
Guy J. Jordan,2004年,Jordan博士成为Orthofix董事。最近,1996年到2002年,Jordan博士担任医疗设备公司CR Bard, Inc.的集团总裁,在那里他有Bard's 全球肿瘤学业务的战略和运营责任以及Bard研究与开发的功能责任。Jordan博士获得了Georgetown University有机化学博士学位以及Fairleigh Dickinson University的MBA学位。目前他还任职于私人医疗保健公司EndoGastric Solutions, Inc., Tangent Medical, Inc.,atheter Connections, Inc.的董事会。
Guy J. Jordan became a director of Orthofix in 2004. Most recently, from 1996 to 2002 Dr. Jordan served as a Group President at CR Bard, Inc., a medical device company, where he had strategic and operating responsibilities for Bard’s global oncology business and functional responsibility for all of Bard’s research and development. Dr. Jordan earned a PhD in organic chemistry from Georgetown University as well as an MBA from Fairleigh Dickinson University. - Guy J. Jordan,2004年,Jordan博士成为Orthofix董事。最近,1996年到2002年,Jordan博士担任医疗设备公司CR Bard, Inc.的集团总裁,在那里他有Bard's 全球肿瘤学业务的战略和运营责任以及Bard研究与开发的功能责任。Jordan博士获得了Georgetown University有机化学博士学位以及Fairleigh Dickinson University的MBA学位。目前他还任职于私人医疗保健公司EndoGastric Solutions, Inc., Tangent Medical, Inc.,atheter Connections, Inc.的董事会。
- Guy J. Jordan became a director of Orthofix in 2004. Most recently, from 1996 to 2002 Dr. Jordan served as a Group President at CR Bard, Inc., a medical device company, where he had strategic and operating responsibilities for Bard’s global oncology business and functional responsibility for all of Bard’s research and development. Dr. Jordan earned a PhD in organic chemistry from Georgetown University as well as an MBA from Fairleigh Dickinson University.
- Maria Sainz
-
Maria Sainz, 2012年11月成为Orthofix的董事,早前自2008年6月至2011年9月是我们的董事。2012年4月,她成为了CardioKinetix Inc.(心脏衰竭相关的医疗设备公司)的总裁、首席执行官和董事。2008年4月至2011年10月,她是Concentric Medical, Inc.(中风后进行机械血栓清除的开发及商业化公司,2011年10月出售给了Stryker Corporate)的总裁和首席执行官。在四个后,她担任the Stryker Neurovascular业务单元总经理,直到2012年4月。2003年至2006年,她是Guidant Corporation心脏外科的总裁。在Boston Scientific收购Guidant之后, Sainz女士领导了Guidant的心脏外科手术和欧洲心脏节律管理业务至Boston Scientific的一体化进程. 2001年至2003年,Sainz女士是Guidant的血管介入全球营销副总裁. Sainz女士获得了the Universidad Complutense de Madrid的学士和硕士学位,American Graduate School of International Management的国际管理硕士学位. Sainz女士分别自2010年11月和2014年1月起担任上市医疗设备公司The Spectranetics Corporation和MRI Interventions, Inc.的董事。
Maria Sainz was elected to our Board effective February 1 2015. Ms. Sainz has served as the CEO of Aegea Medical, a medical device company in the women’s health space focused on the development of technology for endometrial ablation, since May 2018. Prior to that, she served as the President and CEO of Cardiokinetix, a medical device company, from May 2012 until July 2017. She was the President and CEO of Concentric Medical, Inc., a medical technology company, from April 2008 until May 2012. In 2011 Concentric Medical was acquired by Stryker Corporation, where she was named General Manager of the business unit of Stryker Neurovascular. Ms. Sainz led integration activities following the acquisition of Guidant Corporation by Boston Scientific from 2006 to 2008. She served as President of the Cardiac Surgery division of Guidant from February 2003 through July 2006. Ms. Sainz served as Vice President, Global Marketing for the Vascular Intervention division of Guidant from January 2001 through February 2003. Ms. Sainz served as Vice President of the Intermedics Cardiac Rhythm Management business of Guidant in Europe, from 1998 to 2001. Ms. Sainz also serves as a director of Orthofix International, N.V., and Iridex Corporation. - Maria Sainz, 2012年11月成为Orthofix的董事,早前自2008年6月至2011年9月是我们的董事。2012年4月,她成为了CardioKinetix Inc.(心脏衰竭相关的医疗设备公司)的总裁、首席执行官和董事。2008年4月至2011年10月,她是Concentric Medical, Inc.(中风后进行机械血栓清除的开发及商业化公司,2011年10月出售给了Stryker Corporate)的总裁和首席执行官。在四个后,她担任the Stryker Neurovascular业务单元总经理,直到2012年4月。2003年至2006年,她是Guidant Corporation心脏外科的总裁。在Boston Scientific收购Guidant之后, Sainz女士领导了Guidant的心脏外科手术和欧洲心脏节律管理业务至Boston Scientific的一体化进程. 2001年至2003年,Sainz女士是Guidant的血管介入全球营销副总裁. Sainz女士获得了the Universidad Complutense de Madrid的学士和硕士学位,American Graduate School of International Management的国际管理硕士学位. Sainz女士分别自2010年11月和2014年1月起担任上市医疗设备公司The Spectranetics Corporation和MRI Interventions, Inc.的董事。
- Maria Sainz was elected to our Board effective February 1 2015. Ms. Sainz has served as the CEO of Aegea Medical, a medical device company in the women’s health space focused on the development of technology for endometrial ablation, since May 2018. Prior to that, she served as the President and CEO of Cardiokinetix, a medical device company, from May 2012 until July 2017. She was the President and CEO of Concentric Medical, Inc., a medical technology company, from April 2008 until May 2012. In 2011 Concentric Medical was acquired by Stryker Corporation, where she was named General Manager of the business unit of Stryker Neurovascular. Ms. Sainz led integration activities following the acquisition of Guidant Corporation by Boston Scientific from 2006 to 2008. She served as President of the Cardiac Surgery division of Guidant from February 2003 through July 2006. Ms. Sainz served as Vice President, Global Marketing for the Vascular Intervention division of Guidant from January 2001 through February 2003. Ms. Sainz served as Vice President of the Intermedics Cardiac Rhythm Management business of Guidant in Europe, from 1998 to 2001. Ms. Sainz also serves as a director of Orthofix International, N.V., and Iridex Corporation.
- Alexis V. Lukianov
-
Alexis V. Lukianov,2007年12月起,担任本公司董事。1999年7月以来,他一直是NuVasive的总裁、首席执行官、董事;2004年2月起,担任NuVasive的董事长、首席执行官,这是一个上市的医疗器械公司,专注于脊柱疾病手术治疗相关产品的设计、开发和销售。1996年4月至1997年4月,他是脊椎医师执业管理公司BackCare Group的创始人、董事长、首席执行官。1990年1月至1995年10月,他在Medtronic Sofamor Danek担任过各种行政职务,其中包括总裁,这是医疗技术上市公司Medtronic, Inc的子公司,从事开发和生产用于颅骨和脊椎疾病的医疗器械。他是Patriarch Tikhon Russian-American Music Institute的创始人、主席、St. Katherine College的董事。他曾担任BIOCOM、Medical Device Manufacturers Association MDMA的董事、执行委员会成员,前者是区域性的生命科学行业协会,后者是全国性的行业协会。
Alexis V. Lukianov became a director in December 2016 From July 1999 to March 2015 he served as Chief Executive Officer and a director of NuVasive, Inc., a publicly-traded medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders, including serving as Chairman of the Board between 2004 and 2015. From April 1996 to April 1997 Mr. Lukianov was a founder of and served as Chairman of the Board and Chief Executive Officer of BackCare Group, Inc., a spine physician practice management company. From January 1990 to October 1995 Mr. Lukianov held a variety of senior executive positions, including President, with Medtronic Sofamor Danek, Inc., a developer and manufacturer of medical devices to treat disorders of the cranium and spine and a subsidiary of Medtronic, Inc., a publicly-traded medical technology company. Between 1987 and 1990 he was the director of a business unit at Smith & Nephew Orthopaedics that brought limb lengthening technology to the United States from Russia. From 2007 until its acquisition in 2015 by Royal Philips, he served on the Board of Directors of Volcano Corporation, a Nasdaq-listed medical technology company. He has previously served on the boards and the executive committees of BIOCOM, a regional life sciences trade association, and Medical Device Manufacturers Association MDMA, a national trade association. - Alexis V. Lukianov,2007年12月起,担任本公司董事。1999年7月以来,他一直是NuVasive的总裁、首席执行官、董事;2004年2月起,担任NuVasive的董事长、首席执行官,这是一个上市的医疗器械公司,专注于脊柱疾病手术治疗相关产品的设计、开发和销售。1996年4月至1997年4月,他是脊椎医师执业管理公司BackCare Group的创始人、董事长、首席执行官。1990年1月至1995年10月,他在Medtronic Sofamor Danek担任过各种行政职务,其中包括总裁,这是医疗技术上市公司Medtronic, Inc的子公司,从事开发和生产用于颅骨和脊椎疾病的医疗器械。他是Patriarch Tikhon Russian-American Music Institute的创始人、主席、St. Katherine College的董事。他曾担任BIOCOM、Medical Device Manufacturers Association MDMA的董事、执行委员会成员,前者是区域性的生命科学行业协会,后者是全国性的行业协会。
- Alexis V. Lukianov became a director in December 2016 From July 1999 to March 2015 he served as Chief Executive Officer and a director of NuVasive, Inc., a publicly-traded medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders, including serving as Chairman of the Board between 2004 and 2015. From April 1996 to April 1997 Mr. Lukianov was a founder of and served as Chairman of the Board and Chief Executive Officer of BackCare Group, Inc., a spine physician practice management company. From January 1990 to October 1995 Mr. Lukianov held a variety of senior executive positions, including President, with Medtronic Sofamor Danek, Inc., a developer and manufacturer of medical devices to treat disorders of the cranium and spine and a subsidiary of Medtronic, Inc., a publicly-traded medical technology company. Between 1987 and 1990 he was the director of a business unit at Smith & Nephew Orthopaedics that brought limb lengthening technology to the United States from Russia. From 2007 until its acquisition in 2015 by Royal Philips, he served on the Board of Directors of Volcano Corporation, a Nasdaq-listed medical technology company. He has previously served on the boards and the executive committees of BIOCOM, a regional life sciences trade association, and Medical Device Manufacturers Association MDMA, a national trade association.
- Maria Sainz
-
Maria Sainz,2010年11月起在董事会任职。2012年4月起,她在风投支持的心脏衰竭领域医疗器械公司Cardiokinetix Inc.担任总裁和首席执行官。此前,她担任全球医疗科技公司Stryker Corporation神经血管部门Concentric Medical单元的总经理。它2011年10月被私营控股商业化阶段公司Concentric Medical, Inc.收购,该公司制造和销售传递到大脑中消除导致缺血性中风的血栓的微创设备。2008年4月至2011年10月Stryker被并购,她担任Concentric Medical的总裁和首席执行官。1991至2006年,她在美国和欧洲地区的Eli Lilly医疗设备业务和心血管医疗产品制造商Guidant Corporation的心脏节律管理、心脏手术和血管介入等部门担任多个行政职位。2003至2006年,她是Guidant Management Committee成员,担任拥有500名员工的心脏外科部门总裁,在她的领导下,该部门年营业收入从9千万美元增加到1.76亿美元。在Guidant2006年被Boston Scientific Corporation并购之后,她担任Boston Scientific Corporation首席运营官顾问,协助美国和欧洲几个过渡事务,直至2008年初。她现任上市医疗设备公司Orthofix NV的董事,该公司专注于为脊柱和骨科市场开发和交付修复和再生解决方案。她还是MRI Interventions的董事,该公司开发和商业化在大脑和心脏直接进行磁共振成像指导的微创手术平台。
Maria Sainz, CAREER HIGHLIGHTS:Aegea Medical, a medical device company in the womens’ health space focused on the development of technology for endometrial ablation,Chief Executive Officer May 2018 to February 2021. Cardiokinetix, a medical device company, President and Chief Executive Officer (May 2012 to July 2017). Stryker Corporation (acquired Concentric Medical in 2011), General Manager, Stryker Neurovascular, Concentric Medical, a medical technology company, President and Chief Executive Officer (April 2008 to May 2012). Boston Scientific (acquired Guidant Corporation in 2006), Head of Integration (2006 to 2008). Guidant Corporation: President, Cardiac Surgery division (February 2003 to July 2006), Vice President, Global Marketing, Vascular Intervention (January 2001 to February 2003), Vice President, Intermedics Cardiac Rhythm Management, Europe (1998 to 2001). OTHER CURRENT PUBLIC COMPANY BOARDS: Orthofix Medical, Inc.,ShockWave Medical, Inc.. PRIOR PUBLIC COMPANY BOARDS: Iridex Corporation, Spectranetics Corporation, OTHER CURRENT DIRECTORSHIPS: Artio Medical, Inc., Levita Magnetics International Corp. - Maria Sainz,2010年11月起在董事会任职。2012年4月起,她在风投支持的心脏衰竭领域医疗器械公司Cardiokinetix Inc.担任总裁和首席执行官。此前,她担任全球医疗科技公司Stryker Corporation神经血管部门Concentric Medical单元的总经理。它2011年10月被私营控股商业化阶段公司Concentric Medical, Inc.收购,该公司制造和销售传递到大脑中消除导致缺血性中风的血栓的微创设备。2008年4月至2011年10月Stryker被并购,她担任Concentric Medical的总裁和首席执行官。1991至2006年,她在美国和欧洲地区的Eli Lilly医疗设备业务和心血管医疗产品制造商Guidant Corporation的心脏节律管理、心脏手术和血管介入等部门担任多个行政职位。2003至2006年,她是Guidant Management Committee成员,担任拥有500名员工的心脏外科部门总裁,在她的领导下,该部门年营业收入从9千万美元增加到1.76亿美元。在Guidant2006年被Boston Scientific Corporation并购之后,她担任Boston Scientific Corporation首席运营官顾问,协助美国和欧洲几个过渡事务,直至2008年初。她现任上市医疗设备公司Orthofix NV的董事,该公司专注于为脊柱和骨科市场开发和交付修复和再生解决方案。她还是MRI Interventions的董事,该公司开发和商业化在大脑和心脏直接进行磁共振成像指导的微创手术平台。
- Maria Sainz, CAREER HIGHLIGHTS:Aegea Medical, a medical device company in the womens’ health space focused on the development of technology for endometrial ablation,Chief Executive Officer May 2018 to February 2021. Cardiokinetix, a medical device company, President and Chief Executive Officer (May 2012 to July 2017). Stryker Corporation (acquired Concentric Medical in 2011), General Manager, Stryker Neurovascular, Concentric Medical, a medical technology company, President and Chief Executive Officer (April 2008 to May 2012). Boston Scientific (acquired Guidant Corporation in 2006), Head of Integration (2006 to 2008). Guidant Corporation: President, Cardiac Surgery division (February 2003 to July 2006), Vice President, Global Marketing, Vascular Intervention (January 2001 to February 2003), Vice President, Intermedics Cardiac Rhythm Management, Europe (1998 to 2001). OTHER CURRENT PUBLIC COMPANY BOARDS: Orthofix Medical, Inc.,ShockWave Medical, Inc.. PRIOR PUBLIC COMPANY BOARDS: Iridex Corporation, Spectranetics Corporation, OTHER CURRENT DIRECTORSHIPS: Artio Medical, Inc., Levita Magnetics International Corp.
- James F. Hinrichs
-
James F. Hinrichs 于 2014 年 4 月被任命为董事会成员。自 2015 年 4 月起,他担任上市诊断公司 Alere Inc 的执行副总裁兼首席财务官。从 2010 年 12 月到 2015 年 3 月,他担任上市医疗技术公司 CareFusion Corporation 的首席财务官,然后将其出售给 Becton Dickinson。他曾于 2010 年 1 月至 2010 年 12 月担任 CareFusion 的全球客户支持高级副总裁,并于 2009 年 1 月至 2010 年 1 月担任其财务总监高级副总裁。在加入 CareFusion 之前,该公司从 Cardinal Health, Inc. 分拆出来。 ,自 2004 年以来,他在 Cardinal Health 担任多个职位,包括 Cardinal Health 的执行副总裁和公司财务总监,以及其医疗保健供应链服务部门的执行副总裁兼首席财务官。在 Merck & Co 担任了十多年的财务和营销职务后,他加入了 Cardinal Health。他拥有卡内基梅隆大学的商业本科和研究生学位。
James F. Hinrichs was appointed to the Board in April 2014. Since April 2015 he has served as Executive Vice President and Chief Financial Officer of Alere Inc, a publicly traded diagnostic company. From December 2010 through March 2015 he served as Chief Financial Officer of CareFusion Corporation, a publicly traded medical technology company, prior to its sale to Becton Dickinson. He previously served as CareFusion's Senior Vice President, Global Customer Support, from January 2010 to December 2010 and as its Senior Vice President, Controller, from January 2009 to January 2010. Prior to joining CareFusion when it was spun off from Cardinal Health, Inc., he worked since 2004 at Cardinal Health in various positions including Executive Vice President and Corporate Controller of Cardinal Health, and as Executive Vice President and Chief Financial Officer of its Healthcare Supply Chain Services segment. He joined Cardinal Health following over a decade of finance and marketing roles at Merck & Co. He holds undergraduate and graduate degrees in business from Carnegie Mellon University. - James F. Hinrichs 于 2014 年 4 月被任命为董事会成员。自 2015 年 4 月起,他担任上市诊断公司 Alere Inc 的执行副总裁兼首席财务官。从 2010 年 12 月到 2015 年 3 月,他担任上市医疗技术公司 CareFusion Corporation 的首席财务官,然后将其出售给 Becton Dickinson。他曾于 2010 年 1 月至 2010 年 12 月担任 CareFusion 的全球客户支持高级副总裁,并于 2009 年 1 月至 2010 年 1 月担任其财务总监高级副总裁。在加入 CareFusion 之前,该公司从 Cardinal Health, Inc. 分拆出来。 ,自 2004 年以来,他在 Cardinal Health 担任多个职位,包括 Cardinal Health 的执行副总裁和公司财务总监,以及其医疗保健供应链服务部门的执行副总裁兼首席财务官。在 Merck & Co 担任了十多年的财务和营销职务后,他加入了 Cardinal Health。他拥有卡内基梅隆大学的商业本科和研究生学位。
- James F. Hinrichs was appointed to the Board in April 2014. Since April 2015 he has served as Executive Vice President and Chief Financial Officer of Alere Inc, a publicly traded diagnostic company. From December 2010 through March 2015 he served as Chief Financial Officer of CareFusion Corporation, a publicly traded medical technology company, prior to its sale to Becton Dickinson. He previously served as CareFusion's Senior Vice President, Global Customer Support, from January 2010 to December 2010 and as its Senior Vice President, Controller, from January 2009 to January 2010. Prior to joining CareFusion when it was spun off from Cardinal Health, Inc., he worked since 2004 at Cardinal Health in various positions including Executive Vice President and Corporate Controller of Cardinal Health, and as Executive Vice President and Chief Financial Officer of its Healthcare Supply Chain Services segment. He joined Cardinal Health following over a decade of finance and marketing roles at Merck & Co. He holds undergraduate and graduate degrees in business from Carnegie Mellon University.
- Anthony F. Martin
-
Anthony F. Martin。Martin博士在2013年12月任职于董事会。Martin博士在管理生命科学业务执行和非执行董事的角色上拥有超过25年的国际经验。自2006年以来,他在TMA Consultants担任管理合伙人,TMA Consultants是他创办专门从事提供临时管理和生物制药,生命科学研究,医疗设备和诊断公司领导的实体。他目前Immunodiagnostics Systems Holdings plc,Sphere Medical Holding plc和Phico Therapeutics Ltd的非执行董事长,以及Abcam plc的非执行董事。他获得了the University of Manchester Medical School免疫学博士学位和Huddersfield University应用化学一等荣誉学位。Martin博士曾在许多国际生命科学和诊断企业包括British Bio-Technology Products ltd, Celsis International plc,AZUR Environmental、Invitrogen Corporation部门公司the molecular biology,和Molecular Probes Inc.中担任首席执行官。此前,他还曾担任NeuTec Pharma plc and Molecular Insight Pharmaceuticals Inc.主席和Prelude Trust plc及 Invitrogen Corporation的董事会成员。此外,他此前曾任职于Agilent Technologies科学顾问委员会。
Anthony F. Martin was appointed to the Board in December 2013. Dr. Martin has more than 25 years of international experience in managing life science businesses in both executive and non-executive roles. Since 2006 he has been the Managing Partner at Anthony Martin Advisory, an entity that he founded and that specializes in providing strategic guidance and directorship roles to biopharmaceutical, life sciences research, medical device and diagnostic companies. He is currently the Non-Executive Chairman of Phico Therapeutics Ltd. and Peptinnovate Ltd., and a Non-Executive Director of Abcam plc. Dr. Martin is also the Chairman and a Trustee of The Martin Reach, a UK charitable incorporated organization. He gained a doctorate in Immunology from the University of Manchester Medical School, a first class honors degree in Applied Chemistry from Huddersfield University, is a Fellow of the Royal Society of Medicine and a Member of the Institute of Directors. Dr. Martin has previously served as chief executive officer at a number of international life sciences and diagnostic businesses including British Bio-Technology Products ltd, Celsis International plc, AZUR Environmental, the molecular biology division of Invitrogen Corporation, and Molecular Probes Inc. He has also previously served as the Chairman of Immunodiagnostic Systems Holdings plc, NeuTec Pharma plc and Molecular Insight Pharmaceuticals Inc. and as a board member of Prelude Trust plc and Invitrogen Corporation. In addition, he previously served on the scientific advisory Board of Agilent Technologies. - Anthony F. Martin。Martin博士在2013年12月任职于董事会。Martin博士在管理生命科学业务执行和非执行董事的角色上拥有超过25年的国际经验。自2006年以来,他在TMA Consultants担任管理合伙人,TMA Consultants是他创办专门从事提供临时管理和生物制药,生命科学研究,医疗设备和诊断公司领导的实体。他目前Immunodiagnostics Systems Holdings plc,Sphere Medical Holding plc和Phico Therapeutics Ltd的非执行董事长,以及Abcam plc的非执行董事。他获得了the University of Manchester Medical School免疫学博士学位和Huddersfield University应用化学一等荣誉学位。Martin博士曾在许多国际生命科学和诊断企业包括British Bio-Technology Products ltd, Celsis International plc,AZUR Environmental、Invitrogen Corporation部门公司the molecular biology,和Molecular Probes Inc.中担任首席执行官。此前,他还曾担任NeuTec Pharma plc and Molecular Insight Pharmaceuticals Inc.主席和Prelude Trust plc及 Invitrogen Corporation的董事会成员。此外,他此前曾任职于Agilent Technologies科学顾问委员会。
- Anthony F. Martin was appointed to the Board in December 2013. Dr. Martin has more than 25 years of international experience in managing life science businesses in both executive and non-executive roles. Since 2006 he has been the Managing Partner at Anthony Martin Advisory, an entity that he founded and that specializes in providing strategic guidance and directorship roles to biopharmaceutical, life sciences research, medical device and diagnostic companies. He is currently the Non-Executive Chairman of Phico Therapeutics Ltd. and Peptinnovate Ltd., and a Non-Executive Director of Abcam plc. Dr. Martin is also the Chairman and a Trustee of The Martin Reach, a UK charitable incorporated organization. He gained a doctorate in Immunology from the University of Manchester Medical School, a first class honors degree in Applied Chemistry from Huddersfield University, is a Fellow of the Royal Society of Medicine and a Member of the Institute of Directors. Dr. Martin has previously served as chief executive officer at a number of international life sciences and diagnostic businesses including British Bio-Technology Products ltd, Celsis International plc, AZUR Environmental, the molecular biology division of Invitrogen Corporation, and Molecular Probes Inc. He has also previously served as the Chairman of Immunodiagnostic Systems Holdings plc, NeuTec Pharma plc and Molecular Insight Pharmaceuticals Inc. and as a board member of Prelude Trust plc and Invitrogen Corporation. In addition, he previously served on the scientific advisory Board of Agilent Technologies.
- Ronald Matricaria
-
Ronald Matricaria, 2014年3月被任命为董事。他在St. Jude Medical, Inc. 和Eli Lilly and Company, Inc.有着超过35年的医疗设备和制药行业的经验。1993年4月至1999年5月,他是St. Jude Medical, Inc.的总裁和首席执行官;1995年1月至2002年12月担任董事长。在加入St. Jude Medical之前, Matricaria先生在Eli Lilly and Company, Inc.工作了23年,最后担任了Eli Lilly and Company的制药分部执行副总裁及其北美运营总裁。他也是Eli Lilly International Corporation的总裁及其医疗设备分部总裁。他目前也是Volcano Corporation的董事长, Phoenix Children’s Hospital的董事,以及,最近担任Life Technologies Corporation的董事。此外,Matricaria先生也是多家上市和私营公司的董事,包括Home Depot Inc., Diametric Medical Inc., Ceridian Inc., Centocor Inc., Haemonetics Inc., Kinetic Concepts, Inc., Hospira Inc., Cyberonics Inc., Vistacare Inc., Advanced Medical Technology Association AdvaMed, the Pharmaceutical Manufacturers Association International Section, the American Diabetes Association, the American Foundation for Pharmaceutical Education, the National Foundation for Infectious Diseases, the National Retiree Volunteer Center和the Indiana Repertory Theatre,也是the Massachusetts College of Pharmacy and Allied Health Science的理事。他也曾是BioMedical Engineering Institute campaign(为the Institute at the University of Minnesota提供运营基金)的主席。他是the University of Minnesota Foundation的名誉理事。 Matricaria先生拥有the Massachusetts College of Pharmacy的药学学士学位,由于他在药学的突出贡献,他被授予了药学科学荣誉博士和荣誉药学博士。
Ronald Matricaria was appointed to the Board in March 2014. He has more than 35 years of medical device and pharmaceutical experience at St. Jude Medical, Inc. and Eli Lilly and Company, Inc. From April 1993 to May 1999 he served as President and Chief Executive Officer of St. Jude Medical, Inc. and served as Chairman of the Board of Directors from January 1995 to May 2002. Prior to joining St. Jude Medical, Mr. Matricaria spent 23 years with Eli Lilly and Company, Inc., where his last position was Executive Vice President of the Pharmaceutical Division of Eli Lilly and Company and President of its North American operations. He also served as President of Eli Lilly International Corporation, as well as President of its Medical Device Division. He currently serves as a director of Kinaxis Inc. a SaaS based software company traded on the Toronto Stock Exchange. Until recently, he served as Chairman of the Board at Volcano Corporation and as a member of the Boards of Phoenix Children’s Hospital and Life Technologies Corporation. Additionally, Mr. Matricaria previously has served on the board of a number of other public and private companies including Home Depot Inc., Diametric Medical Inc., Ceridian Inc., Centocor Inc., Haemonetics Inc., Kinetic Concepts, Inc., Hospira Inc., Cyberonics Inc., Vistacare Inc., Advanced Medical Technology Association AdvaMed, the Pharmaceutical Manufacturers Association International Section, the American Diabetes Association, the American Foundation for Pharmaceutical Education, the National Foundation for Infectious Diseases, the National Retiree Volunteer Center and the Indiana Repertory Theatre as well as a trustee on the board of the Massachusetts College of Pharmacy and Allied Health Science. He also chaired the BioMedical Engineering Institute campaign, which raised an operating endowment for the Institute at the University of Minnesota. He remains a Trustee emeritus of the University of Minnesota Foundation. Mr. Matricaria holds a bachelor’s degree in pharmacy from the Massachusetts College of Pharmacy and was awarded an honorary Doctor of Science degree in pharmacy, as well as an honorary PharmD degree, in recognition of his contributions to the practice of pharmacy. - Ronald Matricaria, 2014年3月被任命为董事。他在St. Jude Medical, Inc. 和Eli Lilly and Company, Inc.有着超过35年的医疗设备和制药行业的经验。1993年4月至1999年5月,他是St. Jude Medical, Inc.的总裁和首席执行官;1995年1月至2002年12月担任董事长。在加入St. Jude Medical之前, Matricaria先生在Eli Lilly and Company, Inc.工作了23年,最后担任了Eli Lilly and Company的制药分部执行副总裁及其北美运营总裁。他也是Eli Lilly International Corporation的总裁及其医疗设备分部总裁。他目前也是Volcano Corporation的董事长, Phoenix Children’s Hospital的董事,以及,最近担任Life Technologies Corporation的董事。此外,Matricaria先生也是多家上市和私营公司的董事,包括Home Depot Inc., Diametric Medical Inc., Ceridian Inc., Centocor Inc., Haemonetics Inc., Kinetic Concepts, Inc., Hospira Inc., Cyberonics Inc., Vistacare Inc., Advanced Medical Technology Association AdvaMed, the Pharmaceutical Manufacturers Association International Section, the American Diabetes Association, the American Foundation for Pharmaceutical Education, the National Foundation for Infectious Diseases, the National Retiree Volunteer Center和the Indiana Repertory Theatre,也是the Massachusetts College of Pharmacy and Allied Health Science的理事。他也曾是BioMedical Engineering Institute campaign(为the Institute at the University of Minnesota提供运营基金)的主席。他是the University of Minnesota Foundation的名誉理事。 Matricaria先生拥有the Massachusetts College of Pharmacy的药学学士学位,由于他在药学的突出贡献,他被授予了药学科学荣誉博士和荣誉药学博士。
- Ronald Matricaria was appointed to the Board in March 2014. He has more than 35 years of medical device and pharmaceutical experience at St. Jude Medical, Inc. and Eli Lilly and Company, Inc. From April 1993 to May 1999 he served as President and Chief Executive Officer of St. Jude Medical, Inc. and served as Chairman of the Board of Directors from January 1995 to May 2002. Prior to joining St. Jude Medical, Mr. Matricaria spent 23 years with Eli Lilly and Company, Inc., where his last position was Executive Vice President of the Pharmaceutical Division of Eli Lilly and Company and President of its North American operations. He also served as President of Eli Lilly International Corporation, as well as President of its Medical Device Division. He currently serves as a director of Kinaxis Inc. a SaaS based software company traded on the Toronto Stock Exchange. Until recently, he served as Chairman of the Board at Volcano Corporation and as a member of the Boards of Phoenix Children’s Hospital and Life Technologies Corporation. Additionally, Mr. Matricaria previously has served on the board of a number of other public and private companies including Home Depot Inc., Diametric Medical Inc., Ceridian Inc., Centocor Inc., Haemonetics Inc., Kinetic Concepts, Inc., Hospira Inc., Cyberonics Inc., Vistacare Inc., Advanced Medical Technology Association AdvaMed, the Pharmaceutical Manufacturers Association International Section, the American Diabetes Association, the American Foundation for Pharmaceutical Education, the National Foundation for Infectious Diseases, the National Retiree Volunteer Center and the Indiana Repertory Theatre as well as a trustee on the board of the Massachusetts College of Pharmacy and Allied Health Science. He also chaired the BioMedical Engineering Institute campaign, which raised an operating endowment for the Institute at the University of Minnesota. He remains a Trustee emeritus of the University of Minnesota Foundation. Mr. Matricaria holds a bachelor’s degree in pharmacy from the Massachusetts College of Pharmacy and was awarded an honorary Doctor of Science degree in pharmacy, as well as an honorary PharmD degree, in recognition of his contributions to the practice of pharmacy.
高管简历
中英对照 |  中文 |  英文- Doug Rice
Doug Rice。Rice先生2015年4月成为公司的首席财务官。2014年9月4日他加入ORTHOFIX,担任首席会计官;2014年9月27日被任命为临时首席财务官。Rice先生加入Vision Source(一家验光配镜的国际网络供应商),自2012年起他一直担任高级副总裁兼首席财务官。 2007年至2012年被Intel收购,Rice先生担任McAfee(一个安全技术公司)的财务副总裁兼财务主管。2000年至2007年,他曾担任Concentra, Inc.(一个国家医疗服务提供商)的高级副总裁兼财务总监。Rice先生拥有超过25年的财务经验,也包括担任la Madelieine、Allied Marketing Group以及PricewaterhouseCoopers(前身Coopers & Lybrand)的财务领导。他是一名注册会计师,并以优异的成绩持有Southern Methodist University工商管理硕士和工商管理学士学位。
Doug Rice became the Company’s Chief Financial Officer in April 2015. He joined Orthofix as Chief Accounting Officer on September 4 2014 and was appointed to the position of Interim Chief Financial Officer as of September 27 2014. Mr. Rice joined the Company from Vision Source, an international optometric network provider, where he had served since 2012 as Senior Vice President and Chief Financial Officer. Mr. Rice served as the Vice President Finance, Treasurer of McAfee, a security technology company, from 2007 to 2012 when it was acquired by Intel. From 2000 to 2007 he served as the Senior Vice President, Corporate Controller of Concentra, Inc., a national healthcare service provider. Mr. Rice’s over 25 years of finance experience also included finance leadership positions with la Madeleine, Allied Marketing Group as well as PricewaterhouseCoopers formerly Coopers & Lybrand. He is a certified public accountant, and holds an MBA and BBA, with honors, from Southern Methodist University.- Doug Rice。Rice先生2015年4月成为公司的首席财务官。2014年9月4日他加入ORTHOFIX,担任首席会计官;2014年9月27日被任命为临时首席财务官。Rice先生加入Vision Source(一家验光配镜的国际网络供应商),自2012年起他一直担任高级副总裁兼首席财务官。 2007年至2012年被Intel收购,Rice先生担任McAfee(一个安全技术公司)的财务副总裁兼财务主管。2000年至2007年,他曾担任Concentra, Inc.(一个国家医疗服务提供商)的高级副总裁兼财务总监。Rice先生拥有超过25年的财务经验,也包括担任la Madelieine、Allied Marketing Group以及PricewaterhouseCoopers(前身Coopers & Lybrand)的财务领导。他是一名注册会计师,并以优异的成绩持有Southern Methodist University工商管理硕士和工商管理学士学位。
- Doug Rice became the Company’s Chief Financial Officer in April 2015. He joined Orthofix as Chief Accounting Officer on September 4 2014 and was appointed to the position of Interim Chief Financial Officer as of September 27 2014. Mr. Rice joined the Company from Vision Source, an international optometric network provider, where he had served since 2012 as Senior Vice President and Chief Financial Officer. Mr. Rice served as the Vice President Finance, Treasurer of McAfee, a security technology company, from 2007 to 2012 when it was acquired by Intel. From 2000 to 2007 he served as the Senior Vice President, Corporate Controller of Concentra, Inc., a national healthcare service provider. Mr. Rice’s over 25 years of finance experience also included finance leadership positions with la Madeleine, Allied Marketing Group as well as PricewaterhouseCoopers formerly Coopers & Lybrand. He is a certified public accountant, and holds an MBA and BBA, with honors, from Southern Methodist University.
- Bradley R. Mason
Bradley R. Mason。去年年度股东大会开始,Mason先生担任董事。Mason先生在2013年3月重新加入Orthofix作为我们的总裁兼首席执行官,在此前,2008年6月到2009年10月担任北美州集团总裁,2009年11月到2010年10月担任战略顾问。被任命为北美州集团总裁之前,自2003年12月公司收购Breg Orthofix Inc.他担任公司的副总裁。在Orthofix收购之前,Mason先生担任 Breg的总裁和主席,他与其他五个股东成立于1989年的一家公司。Mason先生在医疗器械行业有超过25年的经验,其中一些在dj Orthopedics共同渡过,在那他是创始人兼执行副总裁。自2010年从Orthofix退休,他曾担任各种兼职咨询及顾问角色,包括2012年10月以来担任Orthofix顾问(咨询关系已经于2013年3月13日终)。Mason先生在骨科产品有了38个颁发专利。他最优异成绩毕业于MiraCosta College,获得文科副学士学位和理科副学士学位。
Bradley R. Mason has served as a director since the 2013 Annual General Meeting. Mr. Mason rejoined Orthofix in March 2013 as our President and Chief Executive Officer after previously serving as Group President, North America from June 2008 through October 2009 and as a Strategic Advisor from November 2009 through October 2010. Prior to being appointed as Group President, North America, he had served as a Vice President of the Company since December 2003 when the Company acquired Breg, Inc. Prior to its acquisition by Orthofix, Mr. Mason had served as President and Chairman of Breg, a company he principally founded in 1989 with five other shareholders. Mr. Mason has over 30 years of experience in the medical device industry, some of which were spent with dj Orthopedics formally DonJoy where he became an owner and executive in its early development stage and held the position of Executive Vice President. Since his retirement from Orthofix in 2010 he has served in a variety of part-time consulting and advisory roles, including as a consultant to Orthofix since October 2012 (which consulting relationship has been terminated as of March 13 2013). Mr. Mason is the named inventor on 38 issued patents in the orthopedic product arena. He graduated Summa Cum Laude with an Associate of Arts and Associate of Science degree from MiraCosta College.- Bradley R. Mason。去年年度股东大会开始,Mason先生担任董事。Mason先生在2013年3月重新加入Orthofix作为我们的总裁兼首席执行官,在此前,2008年6月到2009年10月担任北美州集团总裁,2009年11月到2010年10月担任战略顾问。被任命为北美州集团总裁之前,自2003年12月公司收购Breg Orthofix Inc.他担任公司的副总裁。在Orthofix收购之前,Mason先生担任 Breg的总裁和主席,他与其他五个股东成立于1989年的一家公司。Mason先生在医疗器械行业有超过25年的经验,其中一些在dj Orthopedics共同渡过,在那他是创始人兼执行副总裁。自2010年从Orthofix退休,他曾担任各种兼职咨询及顾问角色,包括2012年10月以来担任Orthofix顾问(咨询关系已经于2013年3月13日终)。Mason先生在骨科产品有了38个颁发专利。他最优异成绩毕业于MiraCosta College,获得文科副学士学位和理科副学士学位。
- Bradley R. Mason has served as a director since the 2013 Annual General Meeting. Mr. Mason rejoined Orthofix in March 2013 as our President and Chief Executive Officer after previously serving as Group President, North America from June 2008 through October 2009 and as a Strategic Advisor from November 2009 through October 2010. Prior to being appointed as Group President, North America, he had served as a Vice President of the Company since December 2003 when the Company acquired Breg, Inc. Prior to its acquisition by Orthofix, Mr. Mason had served as President and Chairman of Breg, a company he principally founded in 1989 with five other shareholders. Mr. Mason has over 30 years of experience in the medical device industry, some of which were spent with dj Orthopedics formally DonJoy where he became an owner and executive in its early development stage and held the position of Executive Vice President. Since his retirement from Orthofix in 2010 he has served in a variety of part-time consulting and advisory roles, including as a consultant to Orthofix since October 2012 (which consulting relationship has been terminated as of March 13 2013). Mr. Mason is the named inventor on 38 issued patents in the orthopedic product arena. He graduated Summa Cum Laude with an Associate of Arts and Associate of Science degree from MiraCosta College.